Fate Therapeutics Inc FATE:NASDAQ

Last Price$18.74Cboe Real-Time Last Sale as of 10:20AM ET 8/20/19
Cboe Real-Time Quotes
Realtime quote and/or trade prices are not sourced from all markets
Today's Change-0.25(1.32%)
Bid (Size)$18.70 (200)
Ask (Size)$18.81 (200)
Day Low / High$18.69 - 19.02
Volume29.9 K

View Biotechnology IndustryPeer Comparison as of 08/20/2019


Fate Therapeutics Inc ( NASDAQ )

Price: $18.74
Change: -0.25 (1.32%)
Volume: 29.9 K
10:20AM ET 8/20/2019

OPKO Health Inc ( NASDAQ )

Price: $1.98
Change: -0.04 (1.98%)
Volume: 170.9 K
10:21AM ET 8/20/2019

Momenta Pharmaceuticals Inc ( NASDAQ )

Price: $12.60
Change: +0.17 (1.37%)
Volume: 14.2 K
10:19AM ET 8/20/2019

Epizyme Inc ( NASDAQ )

Price: $13.73
Change: -0.13 (0.94%)
Volume: 26.6 K
10:20AM ET 8/20/2019

Veracyte Inc ( NASDAQ )

Price: $25.43
Change: +0.22 (0.87%)
Volume: 29.2 K
10:21AM ET 8/20/2019

Read more news Recent News

--Analyst Actions: BTIG Research Initiates Coverage on Fate Therapeutics at Buy, PT $27
11:50AM ET 8/09/2019 MT Newswires

Price: 18.44, Change: -0.81, Percent Change: -4.21 ...

--Analyst Actions: Wedbush Raises Price Target on Fate Therapeutics to $26 From $21, Maintains Outperform
8:09AM ET 8/07/2019 MT Newswires

Price: 19.82, Change: +0.55, Percent Change: +2.85 ...

Significant Insider Selling Continues at Fate Therapeutics (FATE)
10:17PM ET 8/05/2019 MT Newswires

There was a notable sale of shares of Fate Therapeutics by an insider today, as revealed in a form 4 document filed with the SEC. One insider -- Dr Amir...

Insider Trends: Fate Therapeutics Insider Extends 90-Day Selling Trend
4:34PM ET 8/02/2019 MT Newswires

On Jul 31, 2019, Director, Dr Amir Nashat, executed a sale of 62,005 shares in Fate Therapeutics (FATE) for $1,397,066. Dr Nashat, after the transactions...

Company Profile

Business DescriptionFate Therapeutics, Inc. operates as a biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorder. The firm programme cellular therapeutics for the treatment of life threatening diseases, hematologic malignancies, genetic disorders and diseases resulting from the dysregulation of the immune system. Its products include ProHema, ProTmune, Adaptive NK, iPSC-derived NK, Programmed CD34 and T cell therapy. The company was founded by Philip Beachy, Sheng Ding, Rudolf Jaenisch, Randall T. Moon, Michael Rudnicki, David Scadden, Leonard Zon, Alexander Rives, Scott Wolchko and John D. Mendlein on April 27, 2007 and is headquartered in San Diego, CA. View company web site for more details
Address3535 General Atomics Court
San Diego, California 92121
Number of Employees104
Recent SEC Filing08/07/20198-K/A
President, Chief Executive Officer & DirectorJ. Scott Wolchko
Chief Scientific OfficerDaniel D. Shoemaker
Vice President-Clinical DevelopmentYu Waye Chu
Senior Vice President-Corporate DevelopmentJim Beitel

Company Highlights

Price Open$18.81
Previous Close$18.99
52 Week Range$10.78 - 22.82
Market Capitalization$1.2 B
Shares Outstanding65.4 M
SectorHealth Technology
Next Earnings Announcement11/07/2019

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / EarningsN/A
Earnings per Share-$1.22
Beta vs. S&P 500N/A
Revenue$4.7 M
Net Profit Margin-934.70%
Return on Equity-50.05%

Analyst Ratings as of 08/08/2019

Consensus RecommendationConsensus Icon
Powered by Factset